Emelie Berglund

Emelie Berglund

Auto-generated profile, based on publicly available information

Emelie Berglund

Prostatype Genomics AB, Nacka Strand, Augustendalsvägen 20, Sweden

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMaja Marklund
Maja Marklund
NSNiklas Schultz
Niklas Schultz
SFStefanie Friedrich
Stefanie Friedrich
EBEmelie Berglund
Emelie Berglund
FTFiras Tarish
Firas Tarish
JLJoakim Lundeberg
Joakim Lundeberg
The molecular mechanisms underlying lethal castration-resistant prostate cancer remain poorly understood, with intratumoral heterogeneity a likely contributing factor. To examine the temporal aspects of resistance, we analyze tumor heterogeneity in needle biopsies collected before and after treatment with androgen deprivation therapy. By doing so, we are able to couple clinical responsiveness and morphological information such as Gleason score to transcriptome-wide data. Our data-driven analysis of transcriptomes identifies several distinct intratumoral cell populations, characterized by their unique gene expression profiles. Certain cell populations present before treatment exhibit gene expression profiles that match those of resistant tumor cell clusters, present after treatment. We confirm that these clusters are resistant by the localization of active androgen receptors to the nuclei in cancer cells post-treatment. Our data also demonstrates that most stromal cells adjacent to resistant clusters do not express the androgen receptor, and we identify differentially expressed genes for these cells. Altogether, this study shows the potential to increase the power in predicting resistant tumors.

11 January 2025 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
AFAdam Fridhammar
Adam Fridhammar
OFOskar Frisell
Oskar Frisell
KWKarin Wahlberg
Karin Wahlberg
EBEmelie Berglund
Emelie Berglund
PRPontus Röbeck
Pontus Röbeck
SPSofie Persson
Sofie Persson
Background The Prostatype score (P-score) is a prognostic biomarker that integrates a three-gene (IGFBP3, F3, and VGLL3) signature derived from prostate biopsy samples, with key clinical parameters, including prostate-specific antigen (PSA) levels, Gleason grade, and tumor stage at diagnosis. The test has demonstrated superior predictive accuracy for prostate cancer outcomes compared with traditional risk categorization systems such as D’Amico. Notably, it reclassifies a higher proportion of patients into the low-risk category, making them eligible for active surveillance. This study assessed the cost-effectiveness of the P-score in comparison with D’Amico and the Swedish National Prostate Cancer Register (NPCR) risk categorization systems. Methods A two-step decision analytic model was developed. The model consisted of a decision tree-informed Markov structure estimating the lifetime outcomes of 60-year-old men with diagnosed prostate cancer. Prostate cancer was classified as low-risk, intermediate-risk, or high-risk using either the P-score or D’Amico. Initial therapy was based on observed treatment patterns from the Swedish NPCR. Costs (SEK, year 2022) and quality-adjusted life years (QALYs) were estimated from a healthcare perspective and discounted at 3% per year; incremental cost-effectiveness ratio (ICER) was the primary outcome. Results The P-score led to cost savings and generated an additional 0.19 QALYs compared with D’Amico. The added costs of the genetic test and higher costs of active surveillance and radiotherapy were counterbalanced by savings from reduced costs of surgery, treatment-related side-effects, and metastatic disease. The gain in QALYs was primarily due to the avoidance of metastatic disease and a reduction in treatment-related side-effects. Conclusions The results of this study suggest that the P-score is likely to be a cost-effective alternative to D’Amico for prognostic evaluation of newly diagnosed prostate cancer in Sweden and compared with NPCR when health-related quality of life was included.

29 May 2025 in BJUI Compass
Verified
Journal Article
Open access
Jacob See-Tong Pang(Feng)Jacob See-Tong Pang(Feng)
Jacob See-Tong Pang(Feng)
PLPo‐Hung Lin
Po‐Hung Lin
EBEmelie Berglund
Emelie Berglund
LXLidi Xu
Lidi Xu
ISI Hung Shao
I Hung Shao
CCCheng‐Keng Chuang
Cheng‐Keng Chuang
Objectives: To evaluate the prognostic performance of the Prostatype® score (P‐score) in the Asian prostate cancer (PCa) cohort and to assess its ability to refine risk stratification compared to the National Comprehensive Cancer Network (NCCN) guidelines. This study aimed to determine whether the P‐score, previously validated in European populations, maintains its predictive accuracy in a genetically and clinically distinct high‐risk Asian cohort, where late‐stage diagnosis is more common.Patients and methods: This retrospective study included 148 PCa patients diagnosed at Taiwan Chang Gung Memorial Hospital between 2012 and 2017. Of these, 56 had primary metastases at diagnosis. The P‐score was calculated based on gene expression in core needle biopsies and clinical data collected from patients' medical records. The primary endpoint was PCa‐specific mortality (PCSM). The secondary endpoints were adverse pathology (AP) and biochemical failure.Results: The P‐score significantly outperformed NCCN in predicting PCSM, achieving a higher C‐index (0.90 vs. 0.73, P < 0.005), which reflects superior prognostic accuracy. Notably, 19.6% of patients were reclassified into different risk categories compared to NCCN, improving risk stratification and potentially altering treatment decisions for nearly one in five patients. The P‐score was also an independent predictor of adverse pathology (P = 0.003, AUC: 0.81) and biochemical failure (P = 0.03, AUC: 0.89).Conclusions: This study validated the P‐score for the first time in a non‐European population, confirming its predictive power in an Asian high‐risk setting. The reclassification of 19.6% of patients suggests that the P‐score refines risk stratification beyond NCCN, offering a more precise distinction between favourable and unfavourable outcomes, enabling more informed treatment decisions. These findings highlight the global applicability of the P‐score and its potential to improve risk assessment and personalized treatment for PCa patients worldwide.

7 January 2026 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
AMAlexandra Mack
Alexandra Mack
TTTrung Duong Tran
Trung Duong Tran
EBEmelie Berglund
Emelie Berglund
GAGerald L. Andriole
Gerald L. Andriole
CAChristopher Alley
Christopher Alley
SFStephen J. Freedland
Stephen J. Freedland
Background: The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate P-score. Previous research found P-score accurately predicts prostate cancer (PC) specific mortality (PCSM) in patients with newly diagnosed clinically localized PC. We evaluated the performance of P-score to predict PCSM in a large, multiethnic cohort from the Veterans’ Administration (VA). Methods: After pathologic review to ensure sufficient tumor tissue, formalin-fixed paraffin-embedded (FFPE) biopsy cores from patients with newly diagnosed PC at the Durham VA were sent to an academic medical center. There, cores were sectioned, RNA extracted, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) tests conducted for IGFBP3, F3, VGLL3, and GAPDH (control). Results were combined with clinical data to generate P-scores. The association between P-score and PCSM was evaluated using c-index, Cox and Fine-Gray models, and decision curve analysis (DCA). Results: Higher P-scores were significantly associated with a higher risk of PCSM (HR = 1.48 per 1 unit increase in P-score, 95% CI: 1.20–1.84, p <0.001) and accurately estimated PCSM (c-index = 0.87). Adding clinical variables to P-score only incrementally improved accuracy. The DCA indicated P-score provided net clinical benefit for patients with PCSM risk between 5% and ~50%. As P-score strongly correlated with risk group, we tested the value of P-score in intermediate-risk patients specifically, where it significantly predicted PCSM (HR 1.43, 95% CI: 1.09–1.86, p = 0.009). Conclusion: In this American cohort of veterans, P-score significantly predicted PCSM. Adding clinical variables minimally improved accuracy. Accuracy remained high in intermediate-risk patients, wherein there is arguably the greatest need for better risk stratification. Given P-scores can be generated rapidly in-house using a standardized RT-qPCR assay, P-score represents a robust new tool to risk-stratify newly diagnosed patients for PC death, thereby minimizing mismatched treatments.